View ValuationKrka d. d 향후 성장Future 기준 점검 2/6Krka d. d (는) 각각 연간 5.5% 및 5.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 6.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 17.4% 로 예상됩니다.핵심 정보5.5%이익 성장률6.80%EPS 성장률Pharmaceuticals 이익 성장10.6%매출 성장률5.8%향후 자기자본이익률17.42%애널리스트 커버리지Low마지막 업데이트16 Jun 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 16Krka, d. d., Annual General Meeting, Jul 09, 2026Krka, d. d., Annual General Meeting, Jul 09, 2026, at 13:00 Central European Standard Time.Reported Earnings • May 15First quarter 2026 earnings released: EPS: €3.69 (vs €4.97 in 1Q 2025)First quarter 2026 results: EPS: €3.69 (down from €4.97 in 1Q 2025). Revenue: €565.8m (up 8.4% from 1Q 2025). Net income: €120.9m (down 21% from 1Q 2025). Profit margin: 21% (down from 29% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.Declared Dividend • Apr 05Dividend of €9.10 announcedShareholders will receive a dividend of €9.10. Ex-date: 21st July 2026 Payment date: 23rd July 2026 Dividend yield will be 0.9%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by both earnings (63% earnings payout ratio) and cash flows (58% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 14% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Mar 12Full year 2025 earnings released: EPS: €13.21 (vs €11.60 in FY 2024)Full year 2025 results: EPS: €13.21 (up from €11.60 in FY 2024). Revenue: €2.04b (up 6.9% from FY 2024). Net income: €403.2m (up 13% from FY 2024). Profit margin: 20% (up from 19% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.공시 • Nov 29+ 5 more updatesKrka, d. d. to Report Fiscal Year 2025 Final Results on Mar 12, 2026Krka, d. d. announced that they will report fiscal year 2025 final results at 8:15 AM, Central European Standard Time on Mar 12, 2026Upcoming Dividend • Jul 15Upcoming dividend of €8.25 per shareEligible shareholders must have bought the stock before 22 July 2025. Payment date: 24 July 2025. Payout ratio is a comfortable 62% and this is well supported by cash flows. Trailing yield: 4.1%. Lower than top quartile of Polish dividend payers (7.2%). Higher than average of industry peers (2.8%).Buy Or Sell Opportunity • Jul 09Now 20% undervaluedOver the last 90 days, the stock has risen 15% to zł834. The fair value is estimated to be zł1,048, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years. Earnings per share has grown by 3.0%. For the next 3 years, revenue is forecast to grow by 5.2% per annum. Earnings are also forecast to grow by 2.7% per annum over the same time period.Declared Dividend • May 18Dividend of €8.25 announcedShareholders will receive a dividend of €8.25. Ex-date: 22nd July 2025 Payment date: 24th July 2025 Dividend yield will be 1.1%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by both earnings (62% earnings payout ratio) and cash flows (70% cash payout ratio). The dividend has increased by an average of 13% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 10% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공시 • May 16Krka, d. d., Annual General Meeting, Jul 10, 2025Krka, d. d., Annual General Meeting, Jul 10, 2025.Reported Earnings • May 15First quarter 2025 earnings released: EPS: €4.97 (vs €3.21 in 1Q 2024)First quarter 2025 results: EPS: €4.97 (up from €3.21 in 1Q 2024). Revenue: €522.1m (up 7.4% from 1Q 2024). Net income: €152.2m (up 54% from 1Q 2024). Profit margin: 29% (up from 20% in 1Q 2024). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Apr 13Full year 2024 earnings released: EPS: €11.60 (vs €10.14 in FY 2023)Full year 2024 results: EPS: €11.60 (up from €10.14 in FY 2023). Revenue: €1.91b (up 5.7% from FY 2023). Net income: €357.0m (up 14% from FY 2023). Profit margin: 19% (up from 17% in FY 2023). The increase in margin was driven by higher revenue. Post-clinical trial products Approved (during full year): 18 Launched (during full year): 10 Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Mar 13Full year 2024 earnings released: EPS: €11.60 (vs €10.14 in FY 2023)Full year 2024 results: EPS: €11.60 (up from €10.14 in FY 2023). Revenue: €1.91b (up 5.7% from FY 2023). Net income: €357.0m (up 14% from FY 2023). Profit margin: 19% (up from 17% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.공시 • Nov 29+ 4 more updatesKrka, d. d. to Report Fiscal Year 2024 Results on Jan 30, 2025Krka, d. d. announced that they will report fiscal year 2024 results at 12:00 PM, Central European Standard Time on Jan 30, 2025Reported Earnings • Nov 15Third quarter 2024 earnings released: EPS: €1.93 (vs €2.11 in 3Q 2023)Third quarter 2024 results: EPS: €1.93 (down from €2.11 in 3Q 2023). Revenue: €449.2m (up 6.9% from 3Q 2023). Net income: €59.2m (down 9.3% from 3Q 2023). Profit margin: 13% (down from 16% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 4% per year.Buy Or Sell Opportunity • Jul 25Now 20% undervaluedOver the last 90 days, the stock has risen 9.9% to zł600. The fair value is estimated to be zł751, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.1% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 4.9% per annum. Earnings are also forecast to grow by 4.6% per annum over the same time period.Reported Earnings • Jul 19Second quarter 2024 earnings released: EPS: €3.99 (vs €2.62 in 2Q 2023)Second quarter 2024 results: EPS: €3.99 (up from €2.62 in 2Q 2023). Revenue: €499.3m (up 8.0% from 2Q 2023). Net income: €123.0m (up 52% from 2Q 2023). Profit margin: 25% (up from 18% in 2Q 2023). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 10% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Jul 16Upcoming dividend of €7.50 per shareEligible shareholders must have bought the stock before 23 July 2024. Payment date: 25 July 2024. Payout ratio is a comfortable 72% but the company is paying out more than the cash it is generating. Trailing yield: 5.1%. Lower than top quartile of Polish dividend payers (7.3%). Higher than average of industry peers (2.2%).Buy Or Sell Opportunity • Jun 05Now 21% undervaluedOver the last 90 days, the stock has risen 4.5% to zł560. The fair value is estimated to be zł707, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.4% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 7.0% per annum over the same time period.Declared Dividend • May 19Dividend of €7.50 announcedShareholders will receive a dividend of €7.50. Ex-date: 23rd July 2024 Payment date: 25th July 2024 Dividend yield will be 1.4%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (69% earnings payout ratio) but not covered by cash flows (166% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 14% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • May 17First quarter 2024 earnings released: EPS: €3.21 (vs €2.87 in 1Q 2023)First quarter 2024 results: EPS: €3.21 (up from €2.87 in 1Q 2023). Revenue: €486.1m (up 6.1% from 1Q 2023). Net income: €98.9m (up 11% from 1Q 2023). Profit margin: 20% (in line with 1Q 2023). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 4% per year.Reported Earnings • Apr 14Full year 2023 earnings released: EPS: €10.14 (vs €11.69 in FY 2022)Full year 2023 results: EPS: €10.14 (down from €11.69 in FY 2022). Revenue: €1.81b (up 5.2% from FY 2022). Net income: €313.9m (down 14% from FY 2022). Profit margin: 17% (down from 21% in FY 2022). The decrease in margin was driven by higher expenses. Post-clinical trial products Approved (during full year): 10 Launched (during full year): 8 Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 7.6% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 4% per year.Reported Earnings • Mar 14Full year 2023 earnings released: EPS: €10.14 (vs €11.69 in FY 2022)Full year 2023 results: EPS: €10.14 (down from €11.69 in FY 2022). Revenue: €1.81b (up 5.2% from FY 2022). Net income: €313.9m (down 14% from FY 2022). Profit margin: 17% (down from 21% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 7% per year.공시 • Dec 01+ 6 more updatesKrka, d. d. to Report Q1, 2024 Results on May 16, 2024Krka, d. d. announced that they will report Q1, 2024 results at 8:15 AM, Central European Standard Time on May 16, 2024Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: €2.11 (vs €2.10 in 3Q 2022)Third quarter 2023 results: EPS: €2.11 (up from €2.10 in 3Q 2022). Revenue: €420.1m (up 9.2% from 3Q 2022). Net income: €65.3m (flat on 3Q 2022). Profit margin: 16% (down from 17% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 7% per year.Reported Earnings • Jul 20Second quarter 2023 earnings released: EPS: €2.62 (vs €4.67 in 2Q 2022)Second quarter 2023 results: EPS: €2.62 (down from €4.67 in 2Q 2022). Revenue: €462.2m (up 8.8% from 2Q 2022). Net income: €80.9m (down 44% from 2Q 2022). Profit margin: 18% (down from 34% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 12% per year.Buying Opportunity • Jul 20Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 5.3%. The fair value is estimated to be zł637, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 4.2% per annum. Earnings is also forecast to grow by 2.6% per annum over the same time period.Upcoming Dividend • Jul 11Upcoming dividend of €6.60 per share at 5.7% yieldEligible shareholders must have bought the stock before 18 July 2023. Payment date: 20 July 2023. Payout ratio is a comfortable 57% and this is well supported by cash flows. Trailing yield: 5.7%. Lower than top quartile of Polish dividend payers (7.1%). Higher than average of industry peers (2.7%).Buying Opportunity • May 24Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be zł633, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 4.7% per annum. Earnings is also forecast to grow by 4.6% per annum over the same time period.Reported Earnings • May 18First quarter 2023 earnings released: EPS: €2.87 (vs €2.91 in 1Q 2022)First quarter 2023 results: EPS: €2.87 (down from €2.91 in 1Q 2022). Revenue: €458.2m (up 5.9% from 1Q 2022). Net income: €89.0m (down 1.5% from 1Q 2022). Profit margin: 19% (down from 21% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.2% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 12% per year.Reported Earnings • Mar 17Full year 2022 earnings released: EPS: €11.69 (vs €9.92 in FY 2021)Full year 2022 results: EPS: €11.69 (up from €9.92 in FY 2021). Revenue: €1.72b (up 9.7% from FY 2021). Net income: €363.3m (up 18% from FY 2021). Profit margin: 21% (up from 20% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth.공시 • Jan 31Krka Reportedly Eyes Promoter Stake in Unichem LaboratoriesKrka, d. d. (LJSE:KRKG) is in discussions to acquire the promoter’s stake in Mumbai-based Unichem Laboratories Limited (BSE:506690), said two people aware of the development. Promoter Prakash Amrut Mody & family owns a 50.93% stake in the listed entity. An acquisition of this stake will trigger an open offer for an additional 26% of equity.공시 • Dec 01+ 6 more updatesKrka, d. d., Annual General Meeting, Jul 06, 2023Krka, d. d., Annual General Meeting, Jul 06, 2023, at 01:00 Central European Standard Time.Reported Earnings • Nov 18Third quarter 2022 earnings released: EPS: €2.10 (vs €2.02 in 3Q 2021)Third quarter 2022 results: EPS: €2.10 (up from €2.02 in 3Q 2021). Revenue: €384.8m (up 4.6% from 3Q 2021). Net income: €65.3m (up 4.1% from 3Q 2021). Profit margin: 17% (in line with 3Q 2021). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 12% per year.Reported Earnings • Jul 22Second quarter 2022 earnings released: EPS: €4.67 (vs €2.93 in 2Q 2021)Second quarter 2022 results: EPS: €4.67 (up from €2.93 in 2Q 2021). Revenue: €425.0m (up 3.0% from 2Q 2021). Net income: €145.3m (up 59% from 2Q 2021). Profit margin: 34% (up from 22% in 2Q 2021). The increase in margin was primarily driven by lower expenses. Over the next year, revenue is forecast to stay flat compared to a 7.2% growth forecast for the industry in Poland. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 17% per year.Upcoming Dividend • Jul 12Upcoming dividend of €5.63 per shareEligible shareholders must have bought the stock before 19 July 2022. Payment date: 21 July 2022. Payout ratio is a comfortable 56% and this is well supported by cash flows. Trailing yield: 5.7%. Lower than top quartile of Polish dividend payers (8.4%). Higher than average of industry peers (2.6%).Reported Earnings • May 20First quarter 2022 earnings released: EPS: €2.91 (vs €2.77 in 1Q 2021)First quarter 2022 results: EPS: €2.91 (up from €2.77 in 1Q 2021). Revenue: €432.5m (up 9.3% from 1Q 2021). Net income: €90.4m (up 4.5% from 1Q 2021). Profit margin: 21% (down from 22% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to stay flat compared to a 5.5% growth forecast for the industry in Poland. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 17% per year.Reported Earnings • Mar 19Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: €9.92 (up from €9.27 in FY 2020). Revenue: €1.57b (up 2.0% from FY 2020). Net income: €309.2m (up 6.3% from FY 2020). Profit margin: 20% (in line with FY 2020). Post-clinical trial products Approved (during full year): 14 Revenue exceeded analyst estimates by 1.2%. Over the next year, revenue is forecast to grow 2.5%, compared to a 7.4% growth forecast for the pharmaceuticals industry in Poland. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 22% per year.Valuation Update With 7 Day Price Move • Feb 28Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to zł430, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 95% over the past three years.Reported Earnings • Nov 19Third quarter 2021 earnings released: EPS €2.02 (vs €1.61 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €368.0m (up 3.2% from 3Q 2020). Net income: €62.7m (up 25% from 3Q 2020). Profit margin: 17% (up from 14% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 31% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Jul 30Second quarter 2021 earnings released: EPS €2.93 (vs €2.40 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: €412.8m (up 21% from 2Q 2020). Net income: €91.5m (up 21% from 2Q 2020). Profit margin: 22% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 23% per year whereas the company’s share price has increased by 25% per year.Upcoming Dividend • Jul 13Upcoming dividend of €5.00 per shareEligible shareholders must have bought the stock before 20 July 2021. Payment date: 22 July 2021. Trailing yield: 4.7%. Lower than top quartile of Polish dividend payers (5.8%). Higher than average of industry peers (2.7%).Reported Earnings • May 22First quarter 2021 earnings released: EPS €2.77 (vs €2.72 in 1Q 2020)The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: €395.8m (down 14% from 1Q 2020). Net income: €86.5m (up 1.0% from 1Q 2020). Profit margin: 22% (up from 19% in 1Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 24% per year and the company’s share price has also increased by 24% per year.Reported Earnings • Apr 17Full year 2020 earnings released: EPS €9.27 (vs €7.73 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €1.53b (up 2.8% from FY 2019). Net income: €291.0m (up 19% from FY 2019). Profit margin: 19% (up from 16% in FY 2019). Post-clinical trial products Approved (during full year): 20 Launched (during full year): 29 Over the last 3 years on average, earnings per share has increased by 24% per year and the company’s share price has also increased by 24% per year.Reported Earnings • Mar 19Full year 2020 earnings released: EPS €9.27 (vs €7.73 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €1.53b (up 2.8% from FY 2019). Net income: €291.0m (up 19% from FY 2019). Profit margin: 19% (up from 16% in FY 2019). Over the last 3 years on average, earnings per share has increased by 24% per year whereas the company’s share price has increased by 22% per year.Is New 90 Day High Low • Dec 23New 90-day high: zł420The company is up 9.0% from its price of zł385 on 24 September 2020. The Polish market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is zł475 per share.Is New 90 Day High Low • Dec 03New 90-day high: zł399The company is up 4.0% from its price of zł383 on 04 September 2020. The Polish market is up 5.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is zł390 per share.공시 • Nov 27+ 6 more updatesKrka, d. d. to Report Q1, 2021 Results on May 20, 2021Krka, d. d. announced that they will report Q1, 2021 results at 8:15 AM, Central European Standard Time on May 20, 2021Reported Earnings • Nov 20Third quarter 2020 earnings released: EPS €1.61The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: €356.4m (up 8.2% from 3Q 2019). Net income: €50.4m (up 55% from 3Q 2019). Profit margin: 14% (up from 9.9% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.이익 및 매출 성장 예측WSE:KRK - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20282,388444385490412/31/20272,266430363495512/31/20262,14941034345353/31/20262,085372353452N/A12/31/20252,041403430529N/A9/30/20252,009399341440N/A6/30/20251,973381310412N/A3/31/20251,946410359471N/A12/31/20241,910357246361N/A9/30/20241,901360201345N/A6/30/20241,871366175317N/A3/31/20241,834324122263N/A12/31/20231,80631488227N/A9/30/20231,816298204307N/A6/30/20231,780298274377N/A3/31/20231,743362307411N/A12/31/20221,717363373468N/A9/30/20221,631369362458N/A6/30/20221,615367331417N/A3/31/20221,602313288362N/A12/31/20211,566309314386N/A9/30/20211,551320271343N/A6/30/20211,540308253326N/A3/31/20211,468292308379N/A12/31/20201,535291280361N/A9/30/20201,563284273365N/A6/30/20201,536267275380N/A3/31/20201,578261233346N/A12/31/20191,493246N/A350N/A9/30/20191,451226N/A347N/A6/30/20191,414213N/A337N/A3/31/20191,372196N/A306N/A12/31/20181,332175N/A290N/A9/30/20181,310163N/A271N/A6/30/20181,291163N/A241N/A3/31/20181,283159N/A272N/A12/31/20171,266153N/A228N/A9/30/20171,250138N/A206N/A6/30/20171,226130N/A219N/A3/31/20171,195111N/A190N/A12/31/20161,174108N/A213N/A9/30/20161,154105N/A262N/A6/30/20161,169116N/A250N/A3/31/20161,176143N/A304N/A12/31/20151,165158N/A278N/A9/30/20151,197172N/A215N/A6/30/20151,192172N/A193N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: KRK 의 연간 예상 수익 증가율(5.5%)이 saving rate(5.3%)보다 높습니다.수익 vs 시장: KRK 의 연간 수익(5.5%)이 Polish 시장(11.8%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: KRK 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: KRK 의 수익(연간 5.8%)이 Polish 시장(연간 4.3%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: KRK 의 수익(연간 5.8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: KRK의 자본 수익률은 3년 후 17.4%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/23 13:32종가2026/06/23 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Krka, d. d.는 9명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Simon MatherBarclaysStephane SumarBNP ParibasJamie ClarkBofA Global Research6명의 분석가 더 보기
공시 • May 16Krka, d. d., Annual General Meeting, Jul 09, 2026Krka, d. d., Annual General Meeting, Jul 09, 2026, at 13:00 Central European Standard Time.
Reported Earnings • May 15First quarter 2026 earnings released: EPS: €3.69 (vs €4.97 in 1Q 2025)First quarter 2026 results: EPS: €3.69 (down from €4.97 in 1Q 2025). Revenue: €565.8m (up 8.4% from 1Q 2025). Net income: €120.9m (down 21% from 1Q 2025). Profit margin: 21% (down from 29% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.
Declared Dividend • Apr 05Dividend of €9.10 announcedShareholders will receive a dividend of €9.10. Ex-date: 21st July 2026 Payment date: 23rd July 2026 Dividend yield will be 0.9%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by both earnings (63% earnings payout ratio) and cash flows (58% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 14% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Mar 12Full year 2025 earnings released: EPS: €13.21 (vs €11.60 in FY 2024)Full year 2025 results: EPS: €13.21 (up from €11.60 in FY 2024). Revenue: €2.04b (up 6.9% from FY 2024). Net income: €403.2m (up 13% from FY 2024). Profit margin: 20% (up from 19% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Nov 29+ 5 more updatesKrka, d. d. to Report Fiscal Year 2025 Final Results on Mar 12, 2026Krka, d. d. announced that they will report fiscal year 2025 final results at 8:15 AM, Central European Standard Time on Mar 12, 2026
Upcoming Dividend • Jul 15Upcoming dividend of €8.25 per shareEligible shareholders must have bought the stock before 22 July 2025. Payment date: 24 July 2025. Payout ratio is a comfortable 62% and this is well supported by cash flows. Trailing yield: 4.1%. Lower than top quartile of Polish dividend payers (7.2%). Higher than average of industry peers (2.8%).
Buy Or Sell Opportunity • Jul 09Now 20% undervaluedOver the last 90 days, the stock has risen 15% to zł834. The fair value is estimated to be zł1,048, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years. Earnings per share has grown by 3.0%. For the next 3 years, revenue is forecast to grow by 5.2% per annum. Earnings are also forecast to grow by 2.7% per annum over the same time period.
Declared Dividend • May 18Dividend of €8.25 announcedShareholders will receive a dividend of €8.25. Ex-date: 22nd July 2025 Payment date: 24th July 2025 Dividend yield will be 1.1%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by both earnings (62% earnings payout ratio) and cash flows (70% cash payout ratio). The dividend has increased by an average of 13% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 10% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공시 • May 16Krka, d. d., Annual General Meeting, Jul 10, 2025Krka, d. d., Annual General Meeting, Jul 10, 2025.
Reported Earnings • May 15First quarter 2025 earnings released: EPS: €4.97 (vs €3.21 in 1Q 2024)First quarter 2025 results: EPS: €4.97 (up from €3.21 in 1Q 2024). Revenue: €522.1m (up 7.4% from 1Q 2024). Net income: €152.2m (up 54% from 1Q 2024). Profit margin: 29% (up from 20% in 1Q 2024). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Apr 13Full year 2024 earnings released: EPS: €11.60 (vs €10.14 in FY 2023)Full year 2024 results: EPS: €11.60 (up from €10.14 in FY 2023). Revenue: €1.91b (up 5.7% from FY 2023). Net income: €357.0m (up 14% from FY 2023). Profit margin: 19% (up from 17% in FY 2023). The increase in margin was driven by higher revenue. Post-clinical trial products Approved (during full year): 18 Launched (during full year): 10 Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Mar 13Full year 2024 earnings released: EPS: €11.60 (vs €10.14 in FY 2023)Full year 2024 results: EPS: €11.60 (up from €10.14 in FY 2023). Revenue: €1.91b (up 5.7% from FY 2023). Net income: €357.0m (up 14% from FY 2023). Profit margin: 19% (up from 17% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Nov 29+ 4 more updatesKrka, d. d. to Report Fiscal Year 2024 Results on Jan 30, 2025Krka, d. d. announced that they will report fiscal year 2024 results at 12:00 PM, Central European Standard Time on Jan 30, 2025
Reported Earnings • Nov 15Third quarter 2024 earnings released: EPS: €1.93 (vs €2.11 in 3Q 2023)Third quarter 2024 results: EPS: €1.93 (down from €2.11 in 3Q 2023). Revenue: €449.2m (up 6.9% from 3Q 2023). Net income: €59.2m (down 9.3% from 3Q 2023). Profit margin: 13% (down from 16% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 4% per year.
Buy Or Sell Opportunity • Jul 25Now 20% undervaluedOver the last 90 days, the stock has risen 9.9% to zł600. The fair value is estimated to be zł751, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.1% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 4.9% per annum. Earnings are also forecast to grow by 4.6% per annum over the same time period.
Reported Earnings • Jul 19Second quarter 2024 earnings released: EPS: €3.99 (vs €2.62 in 2Q 2023)Second quarter 2024 results: EPS: €3.99 (up from €2.62 in 2Q 2023). Revenue: €499.3m (up 8.0% from 2Q 2023). Net income: €123.0m (up 52% from 2Q 2023). Profit margin: 25% (up from 18% in 2Q 2023). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 10% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Jul 16Upcoming dividend of €7.50 per shareEligible shareholders must have bought the stock before 23 July 2024. Payment date: 25 July 2024. Payout ratio is a comfortable 72% but the company is paying out more than the cash it is generating. Trailing yield: 5.1%. Lower than top quartile of Polish dividend payers (7.3%). Higher than average of industry peers (2.2%).
Buy Or Sell Opportunity • Jun 05Now 21% undervaluedOver the last 90 days, the stock has risen 4.5% to zł560. The fair value is estimated to be zł707, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.4% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings are also forecast to grow by 7.0% per annum over the same time period.
Declared Dividend • May 19Dividend of €7.50 announcedShareholders will receive a dividend of €7.50. Ex-date: 23rd July 2024 Payment date: 25th July 2024 Dividend yield will be 1.4%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (69% earnings payout ratio) but not covered by cash flows (166% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 14% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • May 17First quarter 2024 earnings released: EPS: €3.21 (vs €2.87 in 1Q 2023)First quarter 2024 results: EPS: €3.21 (up from €2.87 in 1Q 2023). Revenue: €486.1m (up 6.1% from 1Q 2023). Net income: €98.9m (up 11% from 1Q 2023). Profit margin: 20% (in line with 1Q 2023). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 4% per year.
Reported Earnings • Apr 14Full year 2023 earnings released: EPS: €10.14 (vs €11.69 in FY 2022)Full year 2023 results: EPS: €10.14 (down from €11.69 in FY 2022). Revenue: €1.81b (up 5.2% from FY 2022). Net income: €313.9m (down 14% from FY 2022). Profit margin: 17% (down from 21% in FY 2022). The decrease in margin was driven by higher expenses. Post-clinical trial products Approved (during full year): 10 Launched (during full year): 8 Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 7.6% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 4% per year.
Reported Earnings • Mar 14Full year 2023 earnings released: EPS: €10.14 (vs €11.69 in FY 2022)Full year 2023 results: EPS: €10.14 (down from €11.69 in FY 2022). Revenue: €1.81b (up 5.2% from FY 2022). Net income: €313.9m (down 14% from FY 2022). Profit margin: 17% (down from 21% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 7% per year.
공시 • Dec 01+ 6 more updatesKrka, d. d. to Report Q1, 2024 Results on May 16, 2024Krka, d. d. announced that they will report Q1, 2024 results at 8:15 AM, Central European Standard Time on May 16, 2024
Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: €2.11 (vs €2.10 in 3Q 2022)Third quarter 2023 results: EPS: €2.11 (up from €2.10 in 3Q 2022). Revenue: €420.1m (up 9.2% from 3Q 2022). Net income: €65.3m (flat on 3Q 2022). Profit margin: 16% (down from 17% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 7% per year.
Reported Earnings • Jul 20Second quarter 2023 earnings released: EPS: €2.62 (vs €4.67 in 2Q 2022)Second quarter 2023 results: EPS: €2.62 (down from €4.67 in 2Q 2022). Revenue: €462.2m (up 8.8% from 2Q 2022). Net income: €80.9m (down 44% from 2Q 2022). Profit margin: 18% (down from 34% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 12% per year.
Buying Opportunity • Jul 20Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 5.3%. The fair value is estimated to be zł637, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 4.2% per annum. Earnings is also forecast to grow by 2.6% per annum over the same time period.
Upcoming Dividend • Jul 11Upcoming dividend of €6.60 per share at 5.7% yieldEligible shareholders must have bought the stock before 18 July 2023. Payment date: 20 July 2023. Payout ratio is a comfortable 57% and this is well supported by cash flows. Trailing yield: 5.7%. Lower than top quartile of Polish dividend payers (7.1%). Higher than average of industry peers (2.7%).
Buying Opportunity • May 24Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be zł633, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 4.7% per annum. Earnings is also forecast to grow by 4.6% per annum over the same time period.
Reported Earnings • May 18First quarter 2023 earnings released: EPS: €2.87 (vs €2.91 in 1Q 2022)First quarter 2023 results: EPS: €2.87 (down from €2.91 in 1Q 2022). Revenue: €458.2m (up 5.9% from 1Q 2022). Net income: €89.0m (down 1.5% from 1Q 2022). Profit margin: 19% (down from 21% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.2% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 12% per year.
Reported Earnings • Mar 17Full year 2022 earnings released: EPS: €11.69 (vs €9.92 in FY 2021)Full year 2022 results: EPS: €11.69 (up from €9.92 in FY 2021). Revenue: €1.72b (up 9.7% from FY 2021). Net income: €363.3m (up 18% from FY 2021). Profit margin: 21% (up from 20% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Jan 31Krka Reportedly Eyes Promoter Stake in Unichem LaboratoriesKrka, d. d. (LJSE:KRKG) is in discussions to acquire the promoter’s stake in Mumbai-based Unichem Laboratories Limited (BSE:506690), said two people aware of the development. Promoter Prakash Amrut Mody & family owns a 50.93% stake in the listed entity. An acquisition of this stake will trigger an open offer for an additional 26% of equity.
공시 • Dec 01+ 6 more updatesKrka, d. d., Annual General Meeting, Jul 06, 2023Krka, d. d., Annual General Meeting, Jul 06, 2023, at 01:00 Central European Standard Time.
Reported Earnings • Nov 18Third quarter 2022 earnings released: EPS: €2.10 (vs €2.02 in 3Q 2021)Third quarter 2022 results: EPS: €2.10 (up from €2.02 in 3Q 2021). Revenue: €384.8m (up 4.6% from 3Q 2021). Net income: €65.3m (up 4.1% from 3Q 2021). Profit margin: 17% (in line with 3Q 2021). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 12% per year.
Reported Earnings • Jul 22Second quarter 2022 earnings released: EPS: €4.67 (vs €2.93 in 2Q 2021)Second quarter 2022 results: EPS: €4.67 (up from €2.93 in 2Q 2021). Revenue: €425.0m (up 3.0% from 2Q 2021). Net income: €145.3m (up 59% from 2Q 2021). Profit margin: 34% (up from 22% in 2Q 2021). The increase in margin was primarily driven by lower expenses. Over the next year, revenue is forecast to stay flat compared to a 7.2% growth forecast for the industry in Poland. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 17% per year.
Upcoming Dividend • Jul 12Upcoming dividend of €5.63 per shareEligible shareholders must have bought the stock before 19 July 2022. Payment date: 21 July 2022. Payout ratio is a comfortable 56% and this is well supported by cash flows. Trailing yield: 5.7%. Lower than top quartile of Polish dividend payers (8.4%). Higher than average of industry peers (2.6%).
Reported Earnings • May 20First quarter 2022 earnings released: EPS: €2.91 (vs €2.77 in 1Q 2021)First quarter 2022 results: EPS: €2.91 (up from €2.77 in 1Q 2021). Revenue: €432.5m (up 9.3% from 1Q 2021). Net income: €90.4m (up 4.5% from 1Q 2021). Profit margin: 21% (down from 22% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to stay flat compared to a 5.5% growth forecast for the industry in Poland. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 17% per year.
Reported Earnings • Mar 19Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: €9.92 (up from €9.27 in FY 2020). Revenue: €1.57b (up 2.0% from FY 2020). Net income: €309.2m (up 6.3% from FY 2020). Profit margin: 20% (in line with FY 2020). Post-clinical trial products Approved (during full year): 14 Revenue exceeded analyst estimates by 1.2%. Over the next year, revenue is forecast to grow 2.5%, compared to a 7.4% growth forecast for the pharmaceuticals industry in Poland. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 22% per year.
Valuation Update With 7 Day Price Move • Feb 28Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to zł430, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 95% over the past three years.
Reported Earnings • Nov 19Third quarter 2021 earnings released: EPS €2.02 (vs €1.61 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €368.0m (up 3.2% from 3Q 2020). Net income: €62.7m (up 25% from 3Q 2020). Profit margin: 17% (up from 14% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 31% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Jul 30Second quarter 2021 earnings released: EPS €2.93 (vs €2.40 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: €412.8m (up 21% from 2Q 2020). Net income: €91.5m (up 21% from 2Q 2020). Profit margin: 22% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 23% per year whereas the company’s share price has increased by 25% per year.
Upcoming Dividend • Jul 13Upcoming dividend of €5.00 per shareEligible shareholders must have bought the stock before 20 July 2021. Payment date: 22 July 2021. Trailing yield: 4.7%. Lower than top quartile of Polish dividend payers (5.8%). Higher than average of industry peers (2.7%).
Reported Earnings • May 22First quarter 2021 earnings released: EPS €2.77 (vs €2.72 in 1Q 2020)The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: €395.8m (down 14% from 1Q 2020). Net income: €86.5m (up 1.0% from 1Q 2020). Profit margin: 22% (up from 19% in 1Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 24% per year and the company’s share price has also increased by 24% per year.
Reported Earnings • Apr 17Full year 2020 earnings released: EPS €9.27 (vs €7.73 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €1.53b (up 2.8% from FY 2019). Net income: €291.0m (up 19% from FY 2019). Profit margin: 19% (up from 16% in FY 2019). Post-clinical trial products Approved (during full year): 20 Launched (during full year): 29 Over the last 3 years on average, earnings per share has increased by 24% per year and the company’s share price has also increased by 24% per year.
Reported Earnings • Mar 19Full year 2020 earnings released: EPS €9.27 (vs €7.73 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €1.53b (up 2.8% from FY 2019). Net income: €291.0m (up 19% from FY 2019). Profit margin: 19% (up from 16% in FY 2019). Over the last 3 years on average, earnings per share has increased by 24% per year whereas the company’s share price has increased by 22% per year.
Is New 90 Day High Low • Dec 23New 90-day high: zł420The company is up 9.0% from its price of zł385 on 24 September 2020. The Polish market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is zł475 per share.
Is New 90 Day High Low • Dec 03New 90-day high: zł399The company is up 4.0% from its price of zł383 on 04 September 2020. The Polish market is up 5.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is zł390 per share.
공시 • Nov 27+ 6 more updatesKrka, d. d. to Report Q1, 2021 Results on May 20, 2021Krka, d. d. announced that they will report Q1, 2021 results at 8:15 AM, Central European Standard Time on May 20, 2021
Reported Earnings • Nov 20Third quarter 2020 earnings released: EPS €1.61The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: €356.4m (up 8.2% from 3Q 2019). Net income: €50.4m (up 55% from 3Q 2019). Profit margin: 14% (up from 9.9% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.